3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
14
Terminated
4
Unknown
3
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Recurrence
1
Carcinoma in Situ
1
Interventions
pembrolizumab
20
Gemcitabine
18
Cisplatin
14
Magnetic Resonance Spectroscopy
13
enfortumab vedotin
12
Specimen Handling
10
Cystectomy
10
Docetaxel
8
Mitomycin
7
Standard of Care
6
Cystoscopy
6
Transurethral Resection of Bladder
5
Radiotherapy
5
Carboplatin
5
durvalumab
4
Practice Guidelines as Topic
4
Nivolumab
4
Radiation
3
Multiparametric Magnetic Resonance Imaging
3
Mitozytrex
3
Fluorouracil
3
tislelizumab
2
dehydroftorafur
2
cemiplimab
2
avelumab
2
alvimopan
2
Therapeutics
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Urinary Bladder Neoplasms
×
BCG Vaccine
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled
NCT05037279
2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3
Recruiting
540 enrolled